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The present review updates the current knowledge on the question of whether high fructose consumption is harmful or not and 
details new findings which further pushes this old debate. Due to large differences in its metabolic handling when compared to 
glucose, fructose was indeed suggested to be beneficial for the diet of diabetic patients. However its growing industrial use as a 
sweetener, especially in soft drinks, has focused attention on its potential harmfulness, possibly leading to dyslipidemia, obesity, 
insulin resistance/metabolic syndrome and even diabetes. Many new data have been generated over the last years, confirming the 
lipogenic effect of fructose as well as risks of vascular dysfunction and hypertension. Fructose exerts various direct effects in the 
liver, affecting both hepatocytes and Kupffer cells and resulting in non-alcoholic steatotic hepatitis, a well known precursor of the 
metabolic syndrome. Hepatic metabolic abnormalities underlie indirect peripheral metabolic and vascular disturbances, for which 
uric acid is possibly the culprit.
Nevertheless major caveats exist (species, gender, source of fructose, study protocols) which are detailed in this review and presently 
prevent any firm conclusion. New studies taking into account these confounding factors should be undertaken in order to ascertain 
whether or not high fructose diet is harmful.
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INTRODUCTION
In recent years, there has been increasing interest in the 
role of dietary fructose (F) as a possible health risk. For 
decades, there has been a debate as to whether F, which 
has a lower glycemic index than glucose (G) and does not 
induce insulin secretion, is a good dietary alternative for 
diabetic patients. This important question has never been 
answered. More recently, it has been suggested that the 
worldwide burden of obesity and type 2 diabetes (T2DM) 
in young adults might be linked to a parallel increase in the 
consumption of artificially sweetened food, particularly soft 
drinks.1 Frequently in the United States, beverages (sodas 
and fruit juices) are sweetened by F, which is added as 
high F corn syrup (HFCS). HFCS has suddenly attracted 
attention regarding its responsibility in causing these 
metabolic disturbances. However, it must be noted here that 
this phenomenon particularly applies to the United States 
because countries in Europe and elsewhere have limited the 
use of HFCS. This is one reason, as will be seen later, for 
the ongoing discrepancies and as-yet uncertain conclusions.
The present review describes the various aspects of this 
important clinical question, exposes the reasons for some 
major discrepancies and details some reasons why we are 
missing firm conclusions and what must still be done to 
reach them.
WHAT DO FRUCTOSE PHARMACODYNAMICS 
TELL US?
Intestines
In normal alimentation, F is found in fruits and honey, 
either as pure F or as sucrose (S), which is composed 
of F and G in equimolar amounts. Natural F represents 
approximately 15% of total F intake. The higher sweetening 
capacity of F has led to its use as a frequent additive to liquid 
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and solid foods. As will be seen later, this development has 
major consequences for answering the questions addressed 
in this review.
Although structurally similar, F behaves very differently 
from G; it is absorbed in limited amounts, and most healthy 
subjects exhibit signs of intolerance at a daily F intake of 
approximately 50 g,2 free fatty acids and some amino acids 
favor the absorption of F,3,4 which means that the threshold 
for intolerance may be even lower. F is transported via a 
specific glucose transporter, GLUT5, and exits enterocytes 
via GLUT2 transporters. It is important to note that chronic 
F intake upregulates GLUT5 expression.3 The lipidogenic 
effect of F starts in the intestines because F increases the 
levels of fatty acids associated with ApoB48, which are 
released as chylomicrons.
Hepatocytes
Once in the portal vein, F is rapidly and almost 
completely extracted by the liver; the hepatic first pass is 
close to 100%. Hepatocytes can transform F into various 
metabolites: glucose, glycogen, lactate, and fat. In contrast 
to G, F is rapidly converted into triose-P independently 
of insulin. F is also a good precursor for gluconeogenesis 
because it generates lactate. Approximately 17% of F 
becomes glycogen, and approximately 20-50% of an F load 
leaves the liver as G.5 In healthy individuals, compensatory 
mechanisms reduce other gluconeogenic pathways, 
maintaining constant total hepatic glucose production. Over 
a long period of time, however, F decreases the insulin 
inhibition of hepatic glucose production, leading to hepatic 
insulin resistance. The phosphorylation of F requires high 
levels of ATP, leading to acute states of ATP depletion in 
hepatocytes and possible synthesis of uric acid (discussed 
below).
A typical feature of F is the induction of hypertrigly-
ceridemia (HTG), notably because of reduced clearance. 
This is considered to be the most prominent negative effect 
of F. In addition to its effects on TGs, F also decreases HDL 
cholesterol levels.
KUPFFER CELLS
In the liver, the majority of cells are non-parenchymal 
cells. Sinusoids are lined with a dense net of Kupffer cells 
(KCs) and endothelial cells. KCs make up the largest 
proportion of macrophages in the body; they are strongly 
involved in detoxification and inflammatory reactions, 
liberating TNFα, leukotrienes, interleukins and TGF-α.6 
Interestingly, KCs have a high density of insulin receptors 
and extract up to 50% of a G load. Thus, KCs may play an 
important but hitherto unrecognized and poorly understood 
role in the regulation of metabolic homeostasis.7 The few 
data sets that are presently available appear paradoxical. 
One might expect that KC impairment leads to metabolic 
disturbances because a blockage of KCs has been shown to 
result in hyperinsulinemia8. Furthermore, the elimination 
of KCs by clodronate-encapsulated liposomes was recently 
shown to provoke non-alcoholic steatotic hepatitis (NASH) 
due to the concomitant elimination of protective IL-10.9 
Paradoxically, other models using gadolinium chloride to 
eliminate KCs have shown that this procedure improved 
insulin resistance and NASH induced by high fat10 or S, 
one of the primary sources of F.11 TNFα is considered to be 
responsible for these disturbances. These data are intriguing, 
and it is difficult to know if this result is due to the use of 
gadolinium salt or to a massive overproduction of TNFα, 
which would then overcome the beneficial effects of these 
cells. Whatever the explanation, we suggest that the role 
of KCs requires clarification because this very important 
hepatic tissue might represent a key element in the problem.
WHAT DOES PATHOPHYSIOLOGY TELL US?
Metabolic disturbances
High F (HF) is suspected to be involved in a series of 
diseases linked to metabolic disturbances, the best known 
being HTG and insulin resistance. As will be discussed later, 
several mechanisms are responsible for these direct and 
indirect effects of F.
F metabolism does not seem to differ significantly 
between healthy and diabetic subjects. It impairs triglyceride 
(TG) clearance in both populations, but dyslipidemia is 
higher in subjects who are already resistant to insulin.12 
Experimentally, HF diets have long been used to induce a 
metabolic state that is similar to human metabolic syndromes 
(MSs), namely insulin resistance and hyperlipidemia. 
However, this usually does not result in weight gain13 
although the effects of F might vary among rat strains and 
some studies have reported weight gain in adolescents.14 
In hamsters, fasting glycemia and weight were increased 
after chronic HF feeding.15 In mice, F increased adiposity 
and lipids in the liver, while S did not.16 This finding points 
to possible differences in species reactions to HF, which 
is important to keep in mind when interpreting different 
sets of data. In rats, F is usually given in pellets, but it is 
also efficacious when added to drinking water. According 
to the concentration of F used, it is possible to generate 
groups of animals presenting various symptoms ranging 
from simple insulin resistance to full diabetes. When pure 
F was used instead of HFCS, no postprandial HTG was 
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observed for oral intakes up to approximately 50 g/d.17 HTG 
and fasting ApoB was, however, increased in overweight or 
obese women.18 Fasting increased levels of TG, VLDL-TAG 
and leptin without inducing insulin resistance or ectopic 
fat deposition in healthy males after four weeks of HF 
administration.19 More recently, however, the same group 
reported that just one week of HF administration increased 
ectopic fat deposition in the liver and skeletal muscle, with 
a greater effect seen in the offspring of diabetic parents than 
in healthy controls.20
The lipogenic activity of F can be demonstrated in vitro; 
adding HFCS-55 (a sweetener widely used in the United 
States) to hepatocytes leads to HTG and the elevation of 
lipogenic proteins and oxidative stress. At the same time, 
insulin resistance and endoplasmic reticulum stress are 
increased, and mitochondrial dysfunction is illustrated 
by cytochrome C release.21 This finding fits with the 
mitochondrial disruption seen in human NASH.
In rats, the effects of F appear to be stronger in adults 
than in young animals.22 F is usually administered in high 
doses to rats to rapidly produce insulin resistance, but lower, 
more relevant levels of F also induce G intolerance if they 
are administered over long periods of time.23 An HF diet in 
rats is considered to be a relevant model for human NASH, 
leading to typical hepatic lobular inflammation.24
In humans, a high intake of dietary F or sweetened 
fruit juice (but not whole fresh fruits) leads to impaired G 
tolerance in genetically susceptible individuals.25
In addition to dyslipidemia and insulin resistance/
metabolic syndromes, the F in a daily regimen of two 
or more colas has been shown to increase the risk of 
gallstones26 and chronic kidney disease (stones).27
Vascular disturbances
Because of the high potential of F to glycate proteins 
compared to G, concern has been raised about the possible 
roles of F in cardiovascular complications. The reason 
for this is partly because the acyclic (linear) form of the 
sugar (which is the glycating form) is larger in F than in 
G.28,29 A meta-analysis showed that high F consumption 
increased cardiovascular risk by 24%.30 The direct effects of 
F on protein glycation are questionable, however, because 
F is almost completely metabolized by the intestines 
and liver, leaving little if any intact F in the blood. HF 
is commonly assimilated into soft drinks; however, soft 
drinks (particularly colas) contain many other glycating (or 
glycated) agents. Thus, there is possible confusion about 
the real role of F in in vivo glycation. Some direct glycation 
might occasionally occur when food and drinks come into 
direct contact during eating. Indeed, the initial steps of the 
Maillard reaction occur more rapidly with F than with G, and 
the glycation of food proteins decreases their digestibility.31
The glycation of albumin occurs on Lys-524 and 
leads to the formation of carboxymethyllysine (CML).32 
Interestingly, vegetarians show higher levels of CML than 
normal consumers, which can be explained by their high 
consumption of fruits, honey and vegetables.28 F is known 
to be involved in cataractogenesis.33 However, this is more 
likely to be due to intracellular F formation resulting from 
the sorbitol pathway; when F synthesis increases, it can 
glycate lens crystalline.34
Atheromatous plaques are increased in hyper-
cholesterolemic rabbits when F is added to their diet.35 F is 
also suspected to cause hypertension (HT); acute F intake 
has been shown to increase blood pressure and heart rate 
in humans.36,37 In rats, an HF diet does not automatically 
generate HT; it seems that only some rat strains develop HT, 
which is dependent on an animal’s age and diet protocol. 
This phenomenon may be due to the varying intra- and 
interspecies sensitivity toward F; indeed, rats, in contrast to 
humans, possess active uricase.38,39
Vascular reactivity is modified with chronic HF diets, 
as endothelial dysfunction most likely occurs due to the 
inhibition of NO synthesis by F.40 Our experiments showed 
an abnormal reactivity of small terminal arterioles in the 
skeletal muscles of chronically F-fed rats.41
Finally, it is important to note that F also increases PAI-
1,42,43 a fibrinolytic factor that is known to be involved in the 
pathology of both metabolic and vascular disturbances of 
metabolic syndromes.44
MECHANISMS INVOLVED IN FRUCTOSE-IN-
DUCED DISTURBANCES
Direct effects in splanchnic organs
In contrast to G, F does not increase insulin secretion, 
which is considered to be potentially beneficial for diabetic 
patients. However, as described earlier, the primary 
negative side effect of F is its ability to increase lipid levels, 
especially TG. F increases both intestinal and hepatic 
production of atherogenic lipid particles,45 in part through 
chylomicron assembly and secretion.46 Because F may even 
reduce insulin secretion, TG clearance also decreases.47 
The quantitative effect of F on lipogenesis is a topic of 
debate. F affects the partitioning of fatty acids toward their 
esterification, which has been shown in isolated perfused 
livers.48,49 In addition, F increases phosphofructokinase 
mRNA as well as G-6PDH and CHREB50 and fatty acid 
synthase activities.51 These effects lead to hepatic lipid 
loading, resulting in NASH (of which an HF diet is a 
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relevant model in rats). The combined negative effects 
on liver lipid content and lactate and lipid output52 makes 
this organ a crucial effector of HF-induced metabolic 
disturbances. Independently of an MS diagnosis, patients 
presenting NASH were found to consume more soft drinks 
than healthy subjects.53 Interestingly, when moderate intake 
levels of various sweeteners were compared in rats during 
a ten-week period, both F and HFCS increased alanine 
aminotransferase activity, although no other differences were 
observed.54 These data show that the first premises of fatty 
liver can be seen even following moderate F consumption. 
Figure 1 depicts the major fate of F in the splanchnic area as 
well as some differences between F and G.
Recently, the involvement of intestinal bacterial flora in 
the regulation of metabolic homeostasis has been the subject 
of intense interest.55,56 In particular, studies have revealed that 
NASH is associated with intestinal bacterial overgrowth and 
increased intestinal permeability, leading to the endotoxin-
dependent activation of KCs.55 This effect was also shown 
with an HF diet in rats.57 Thus, intestinal effects may add to 
hepatic effects as causal effectors of HF-linked metabolic 
abnormalities.
While F intolerance does not seem to differ between 
normal subjects and those suffering from irritable bowel 
syndrome,58,59 an improvement in F intolerance was observed 
in 1/3 of these patients after F restriction.60 Conversely, F and 
fructans may induce irritable bowel syndrome and intestinal 
permeability.55,61-63
Indirect metabolic effects
By increasing the liver lipid content and provoking HTG, 
F leads to global metabolic derangements that are typical 
of MSs, eventually leading to T2DM. Several studies have 
shown that HF induces hepatic insulin resistance, resulting 
in an elevated G output due to the lack of gluconeogenesis 
suppression. Once in the circulation, TGs may accumulate in 
skeletal muscle cells and induce peripheral insulin resistance.
Figure 1 - Fructose is absorbed in the intestine by GLUT5 and exits enterocytes via GLUT2 transporters. It is taken up by Kupffer cells and hepatocytes, 
where it enters various metabolic pathways that largely differ from those of glucose. Fructose is partly transformed into uric acid, which may cause metabolic 
and vascular disturbances in peripheral tissues.
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High energy intake
It has been suggested that energy intake is higher with 
oral F than with oral G. The reasons for this belief are the 
following: 1) the thermic effect of F is higher than G because 
of high ATP consumption, and 2) it was observed that the 
satiety phenomenon normally regulating food intake did not 
always operate after chronic F. F lowers ghrelin and leptin 
levels to a lesser degree than does G, resulting in lower food 
intake suppression.1,3 This phenomenon applies mainly to 
liquid F, leading to a higher energy balance than F in solid 
food.64,65 When sweetened beverages were taken together 
with meals, a higher mean energy intake of 104 kcal was 
measured.66 Nevertheless, the “energy balance” hypothesis 
of HF is still a subject of debate.67
Is uric acid the culprit?
Uric acid (UA) is a major antioxidant, but, like most 
molecules of this category,68 it can also induce opposite 
effects if concentrations are sufficiently high.69 There are 
likely to be concentration thresholds delineating positive 
from negative effects of such substances; acute and even 
relatively high UA levels protect against oxidative stress70, 
but chronically elevated UA levels are linked to MSs, 
reduced adiponectin and elevated E-selectin, in parallel with 
positive effects such as reduced nitrotyrosine and increased 
total antioxidant capacity.71 Thus, high UA levels could be 
a compensatory mechanism that counteracts the oxidative 
stress related to metabolic or vascular disturbances.72 
In vitro UA increases NADPH oxidase activity and 
oxidative stress in adipocytes, leading to increased p38 
MAP kinase activity and insulin resistance.73 UA levels 
correlate with 24-h urinary excretion, waist circumference, 
insulin concentrations and the HOMA index, which are 
all indices of a MS.74 High insulin levels reduce renal 
UA excretion, suggesting that hyperuricemia results 
from a combination of stimulated formation and reduced 
elimination. In adolescents, body mass index and a number 
of MS components correlate with UA.75 In the San Bernardo 
Study, UA was a good predictor of T2DM in older adults 
with impaired fasting glycemia.76 Elevated UA was shown 
to be linked to NASH independently of body mass index.77-80 
In elderly male subjects, high levels of UA were correlated 
with MS components and elevated levels of PAI-1.81 Thus, 
it seems that at any age, high levels of UA are linked to MS. 
Decreasing UA levels in rats with allopurinol prevents MS, 
as shown by reductions in insulin, TG and weight.40 
On the vascular side, high levels of UA are linked to 
cardiovascular diseases, especially HT.82-86 If patients are 
already at risk, then UA represents a serious problem.87,88 
Mechanisms that are responsible for the deleterious 
UA effects are linked to increased C reactive protein, 
inflammation and reduced NO production, thereby 
hampering vascular reactivity.38,82,84,89
HF increases UA formation as a consequence of ATP 
consumption and high synthesis of AMP, which is then 
deaminated to form UA.3,90 Several studies have shown 
that HF increases UA levels. However, in the first phase of 
the Nanes III study, MS was not linked to UA in subjects 
who consumed diet soft drinks91. UA is known to be 
responsible for gout due to the deposition of monosaccharide 
urate crystals; this effect is strongly related to diet.92 In 
a prospective cohort study over 12 years, F intake was 
correlated with gout regardless of whether sweetened soft 
drinks, fruit juices or F-rich fresh fruits were consumed.77 
However, while this manuscript was in its final phase, a new 
publication showed that an analysis of more recent data from 
the Nanes III database (>9000 subjects) failed to confirm 
an association between F and UA. Thus, over a long time 
period, UA might not be as harmful in an HF diet as was 
initially claimed, which is in agreement with other reports.93
FRUCTOSE VS. OTHER SUGARS
A long-lasting controversy exists regarding the 
harmfulness of F versus other sugars because HFCS is now 
commonly used to sweeten drinks and food. Two questions 
must therefore be addressed: 1) how does “pure” F compare 
with S, a sugar containing one moiety of F, and 2) how 
does F compare with G? It is evident that such studies can 
easily be biased if energy equivalents are not matched in 
the clinical investigations. Most studies comparing F and 
S have shown that both sugars behave in essentially similar 
manners, pointing to the fact that F is actually the culprit.94-97 
No differences in energy balance were found between 
HFCS, S and milk.98 When compared to G, HFCS and S 
always lead to higher TG or glucose/insulin responses over 
a 24-h period.99 In a study investigating the effects of 34% 
F in 3 different diets (F, F+G and S), a reduction in insulin 
sensitivity in rats was observed in every regimen.97 Several 
studies have compared F and G, and in a one-week study, F 
increased VLDL more than G, but intramuscular lipids were 
higher with G.100 Essentially the same qualitative difference 
was found in another study that extended the comparison 
to one month.96 Giving sweetened beverages to overweight 
or obese subjects for up to 10 weeks showed that F but 
not G increased lipid synthesis and visceral adiposity and 
reduced insulin sensitivity; G administration led to increased 
subcutaneous fat, which is relatively harmless.101 When F 
or G was administered with meals, obese patients showed 
lower insulin and leptin levels but increased postprandial 
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TGs; HTG lasted for over 24 hours in the insulin-resistant 
subgroup.12
Altogether, these data show that F has roughly the same 
harmfulness whether it is administered as a concentrate such 
as HFCS or as sucrose. When the comparison is made with 
G, however, there are strong qualitative differences.
Therapeutic effects
Various clinical studies have shown that reducing F 
intake improves ones’ metabolic situation, which is expected. 
Thus, intestinal side effects due to F intolerance or excess 
F in food can be improved by a F-limited diet. Metabolic 
changes such as abdominal fat deposition, insulin resistance, 
oxidative stress and HT are improved by treatment with the 
antidiabetic metformin.37,102-105
Caveats and limits of the actual dataset
As is often found in nutritional studies, many factors, 
which can be controlled or not controlled, can bias 
interpretations of data. As a consequence, our present 
knowledge must consider and eventually investigate these 
factors before delivering clear-cut conclusions.
Species
As discussed above, differences in metabolic reactions to 
F have been described among various species: intra-species 
differences among rat strains, inter-species differences 
among mice, rats and hamsters and differences between 
rodents and humans. The presence of uricase in rats usually 
requires the utilization of high F concentrations in these 
animals, particularly when researchers wish to produce 
pathological individuals rapidly.
Type of food
It is known that the source of F partly determines its 
harmfulness; not only is it different among fresh fruits, fruit 
juices and sweetened soft drinks, but some sources, such as 
honey, appear to be much safer than others. Furthermore, 
several studies have shown that hormonal and metabolic 
reactions are more pronounced with liquid F intake than with 
solid F intake, likely because of the bypass of the satiety 
process with liquid F.
Another important caveat is that most clinical studies 
use soft drinks as the source of F. However, usually other 
parameters, such as daily alimentary habits or lifestyle 
(e.g., food type, activity levels) can affect ones’ metabolism. 
Focusing on F soft drinks as the sole cause of metabolic 
modifications limits the power of the data. The same holds 
true for vascular disturbances because colas and other soft 
drinks contain many other molecules that could interfere 
with vascular reactivity or induce glycation.
Protocols
a) Study Duration
One major aspect of study protocols is the duration 
of the study. Available data have been obtained primarily 
from acute (2-24 h) or mid-term (1-4 weeks) administration 
of F; only some data have been obtained from long-
term investigations. It is clear that acute and short-term 
administration of moderate and even high F will cause 
tissues to react against what they might sense as an 
aggression. We know that metabolic disturbances take 
years to manifest as clinical symptoms due to stepwise 
developing compensations, metabolic adaptations and new 
equilibrium levels (the development of T2DM is a good 
example). Concerning F, the UA aspect may also illustrate 
how an initially positive reaction (hyperuricemia) may turn 
into a negative one. Acute and chronic F administration can 
yield different results. This has been observed for TG levels, 
which were increased in acute but not chronic HF diets.101 
Moreover, a recent report did not observe a correlation 
between F and UA over long time periods.93
b) Gender/Populations
The relatively large number of studies published in recent 
years can be divided into various categories of subjects or 
patients: young, old, healthy, overweight/obese, and diabetic. 
It is understandable that data might look very different 
among these populations. Ethnicity is another possible 
confounder because we know that certain populations have 
greater risks of developing insulin resistance, obesity and/
or MSs. For F, gender may play a role. Differences in most 
domains of physiology between males and females have 
become increasingly recognized in the last 5-10 years. 
This may also apply to HF. For example, it is known that 
female rats are largely protected compared to males. Insulin 
sensitivity decreases to a much larger extent in males106, and 
generally only males develop HT. The same effect holds true 
for humans; a careful examination of the literature shows a 
more severe picture in males than in females. In adolescents, 
weight gain under HF conditions was higher in males than in 
females.14 Furthermore, TG levels were higher in males than 
in females under HFCS or S administration conditions.99 
The incidences of hyperuricemia and MS were higher in 
males than in females.79 Finally, in a study of Japanese 
subjects, UA increased the incidence of MS in males but not 
in females.107
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c) Dosage
As discussed previously, F is only partly absorbed and 
rapidly leads to intestinal intolerance, which illustrates 
the fact that an HF condition is very different from a low 
F condition. However, most studies deal with high or very 
high F concentrations, which are not relevant to daily 
F consumption in humans, even if one considers ‘cola-
addicted’ young people. Moreover, many studies were 
performed in the United States using HFCS, a sweetener 
that is not used or is used only in limited amounts in many 
other countries. Thus, extreme caution should be taken when 
trying to develop firm conclusions.17 In rats, moderate intake 
of various sweeteners (F, HFCS or agave) for 3 nights per 
week during a 10-week period increased serum alanine 
aminotransferase levels, but no other serious disturbances, 
such as those seen with HF, were observed.54 In humans, the 
deleterious effects seen with 20-25% F as an energy source 
were not observed when more realistic quantities of 4-12% 
F were investigated.96
CONCLUSIONS
The controversy that has existed for the last 10 years 
regarding the potential harmfulness of excess fructose is 
legitimate in view of the dramatic increases in both sweetened 
beverage consumption and the burdens of obesity, MS and 
T2DM.108 There is no doubt from many preclinical and clinical 
studies that HF can induce negative effects on both energy 
metabolism and blood vessels (summarized in Figure 2). 
Unfortunately, the vast majority of the studies were 
performed using protocols in which the duration or dosage 
of F administration was not relevant to common daily usage 
in the general population. Nevertheless, the merit of these 
studies was to provide valuable information as to what 
can be expected from excessive F intake and the nature 
of the underlying mechanisms. However, many important 
confounding factors were ignored, which makes data 
interpretation too hazardous to draw conclusions about the 
deleterious nature of HF.
Assuming there is no F intolerance, we infer from the 
available dataset that F is harmless in healthy individuals, 
at least at levels below 50-100 g/d. However, it also appears 
clear that individuals at risk for metabolic syndromes, 
T2DM or cardiovascular diseases should be cautious because 
evidence shows that they are much more susceptible to HF 
than the general population. Thus, the controversy continues, 
and new protocols that take into account our present 
knowledge and eliminate the aforementioned confounding 
factors are required. From the available literature, four main 
aspects of F intake appear to be particularly important: a) 
the use of “natural” F sources (sucrose) instead of HFCS 
or sweetened soft drinks (which contain many additional 
substances), b) the use of relevant F concentrations based 
on existing data about common daily F consumption in 
the general population, c) the mixing of male and female 
subjects and d) the investigation of moderately elevated F 
over long periods of time.
Figure 2 - Summary of short- and long-term metabolic and vascular disturbances and the underlying mechanistic pathways induced by high fructose intake.
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